<DOC>
	<DOC>NCT02668588</DOC>
	<brief_summary>This is a multicentre, double blind, randomized placebo controlled trial to assess the effect of LF-PB on seroma formation in women with breast cancer undergoing Axillary Lymph Node Dissection (ALND). Recruited patients will be randomly assigned to receive LF-PB 30 mg or placebo.</brief_summary>
	<brief_title>Extended-release of Octreotide (LF-PB) for the Treatment of Seroma</brief_title>
	<detailed_description>The study will randomize between 24 and 72 subjects that received an ALND. A staged adaptive design is employed with two intermediate analyses and a final analysis. The first interim analysis at 24 treated subjects (at least 12 in each group) and the second at 48 treated subjects (at least 24 in each group).</detailed_description>
	<mesh_term>Seroma</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Signed informed consent form; Undergoing breast cancer surgery with axillary lymph node dissection during the current clinical trial; Negative serum pregnancy test for women of childbearing potential; Aspartate aminotransferase and alanine aminotransferase &lt; 2 x the upper limit of normal; ECOG PS â‰¤ 1. Previous axillary surgery on the same armpit (sentinel lymph node surgery is not exclusionary); Previous radiotherapy within five years from study drug administration on the same armpit undergoing surgery in this study; Concomitant participation to other clinical trial; Uncontrolled diabetes; Cholelithiasis; Human immunodeficiency virus or hepatitis B or C by screening serology; Uncontrolled hypothyroidism: if patient is being administered Eutirox/ Levothyroxine (or analogues) and levels of T3, T4 and TSH are confirmed to be within the normal ranges at screening, the patient can be enrolled in this study; Pregnant or lactating; Ascertained or presumptive hypersensitivity to the active principle and/or the ingredients of the study drug formulation; Corrected QT (using the Bazett formula, QTc) interval at screening or baseline &gt; 450 msec (as the mean of 3 consecutive readings 5 minutes apart); Presence of any disease or use of concomitant medication known to increase the QT interval; Clinically significant or relevant abnormal medical history, vital sign, physical examination or laboratory evaluation finding; Corticosteroid treatment on a longterm basis (i.e. treatment for more than 3 consecutive days); Current or recurrent disease that could affect the results of the clinical or laboratory assessment required for the study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>